Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2005

View Archived Issues

Update on TGN-255 in the prevention of thrombosis

Add-on topiramate prevents body weight gain in schizophrenics treated with antipsychotics

Novel delivery of contortrostatin provides enhanced potential for clinical development

Halofuginone modulates T-cell functional activity

Cell death pathways investigated in TH-9402-mediated cytotoxicity

BMS-593214: a novel inhibitor of FVIIa

Natriuretic peptides may help predict outcome of patients with nonischemic CHF

Urocortin 2 shows promise in the treatment of congestive heart failure

Clinical data confirm the efficacy of solifenacin in overactive bladder

AL-208 set to enter phase I trials

Enrollment completed in U.S. phase I study of cetilistat for obesity

Agenix contracts Diosynth for manufacturing of ThromboView

BioSante licenses contraceptive technology from Wake Forest University

YM BioSciences licenses oncology compounds from U. of Saskatchewan

Phase II comparative study of R-112 for allergic rhinitis opens enrollment

AmpliMed licenses FB-642 and other compounds from UTR

CytoGenix forms research collaboration with Imperial College London

Encore awarded SBIR grant for work in neuroinflammation

Cenix delivers therapeutic targets to Bayer

Phase II trial begins for OGX-011 for NSCLC

Velcura and Nippon Chemiphar collaborate on osteoporosis drugs

NS-2330 results do not warrant phase III studies in Alzheimer's, Parkinson's

Pfizer submits Sutent NDA

Bioequivalence studies continue for fixed-dose Truvada/Sustiva product

Recent patents describe new antiinfective agents

New agents for treating obesity disclosed by Procter & Gamble

Novel therapeutics for fibroproliferative diseases reported by Scios

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...